25 results about "S100A8" patented technology

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention belongs to the field of medicine, and relates to a construction method of a pneumonia severity prediction model and the prediction model.The construction method comprises the steps that 1, a serum sample of a patient infected by mycoplasma pneumonia is obtained; 2) detecting the content of S100A8 / A9 protein in the serum sample; 3) establishing a data set according to the patient infected by mycoplasma pneumonia, wherein the data set comprises a training set and a verification set; 4) constructing a regression model for the content of the S100A8 / A9 protein by adopting a lasso regression mode; and 5) training the regression model by using the training set to obtain a pneumonia severity prediction model. The invention provides the construction method of the pneumonia severity prediction model which has good prediction performance and good clinical applicability and can improve the accuracy of risk stratification of mycoplasma pneumonia patients, and the prediction model.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

To provide a biomarker for determining the severity and / or activity of atopic dermatitis.SOLUTION: Disclosed is a biomarker comprising at least one selected from the group consisting of S100A6, S100A8, Lipocapin-2, Fibrinogen, Calcitonin, VWF, Cardiotrophin-1, CystatinA, FGF-18, and Ubiquitin + 1.SELECTED DRAWING: None

The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.

Disclosed herein are compositions and methods for predicting response to a BET inhibitor based on the expression level of S100A8 and ER stress response genes. Also disclosed are methods of sensitising subjects found to be resistant using one or more of a S100A8 inhibitor, an ER stress inducing agent and / or a c-KIT inhibitor.

The present application provides an anti-S100A8 / A9 antibody and use thereof. The antibody or antigen-binding fragment thereof, and mutants thereof, provided by the present application, can block the biological functions of S100A8 / A9. The antibody or antigen-binding fragment thereof provided by the present application is expected to be developed into a clinical drug, with the aim of reducing the myocardial infarct size in acute myocardial infarction (AMI) patients, lowering the incidence of heart failure, and providing lifelong benefit to the AMI patients. The present application has significant clinical implications and development value.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

A use of S100A8 / A9 in assessing the severity of infectious diseases, and a use of a biomarker (S100A8 / A9) and / or a substance for detecting the biomarker in the preparation of a product for assessing the severity of infectious diseases. By detecting the level of S100A8 / A9 in serum or plasma, the severity of infectious diseases is rapidly and accurately assessed, thereby simplifying an assessment process and improving accuracy, and the present invention is suitable for various infectious diseases. The biomarker exhibits high sensitivity and good specificity; by assessing the severity of diseases, the present invention provides decision-making support for clinicians, and provides more precise treatment schemes for patients, thereby improving therapeutic efficacy and the quality of life of the patients; and additionally, optimal disease management is achieved, the medical burden on patients' families and society is reduced, and the present invention has favorable and broad clinical application value.

The present application relates to the field of biotechnology, in particular to the use of CD300LD inhibitors in the preparation of products for preventing, diagnosing or treating tumors, CD300LD inhibitors regulate the migration and function of PMN-MDSC cells by regulating S100A8 / A9 in its downstream signaling pathway, and play an important role in the establishment of tumor microenvironment; CD300LD inhibitors can effectively inhibit the development of various solid tumor mouse models, and have significant anti-tumor synergistic effect with PD1 antibodies; in the stage when the tumor has been established, the application of CD300LD inhibitors can significantly inhibit the development of tumors. The present application provides a new target and idea for tumor immunotherapy.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of S100A8 in preparation of a medicine for preventing / treating bladder infection after spinal cord injury. The S100A8 can be used as a prevention target of bladder infection after potential spinal cord injury, and after the S100A8 is perfused into the bladder, the colony count of the bladder tissue is obviously reduced, so that the S100A8 has an infection prevention effect; meanwhile, the damage repair capacity of the bladder epithelium is remarkably improved, the compound can be used as a prevention / treatment target spot for preventing bladder infection after spinal cord injury, and a new thought is provided for clinical prevention and treatment of bladder infection after spinal cord injury.

This invention discloses secretory proteins of pluripotent stem cells (EPSCs), combinations thereof, and their application in the preparation of agents for delaying the aging of human mesenchymal stem cells (MSCs). The application of S100A9 protein, S100A8 protein, GAPDH protein, or any combination thereof in the preparation of agents for delaying the aging of human mesenchymal stem cells (MSCs); the amino acid sequence of the S100A9 protein is shown in SEQ ID NO.1, the amino acid sequence of the S100A8 protein is shown in SEQ ID NO.3, and the amino acid sequence of the GAPDH protein is shown in SEQ ID NO.5. This invention studies the secretory proteins of EPSCs to discover and explore anti-aging factors, identifies secretory proteins with the effect of delaying MSC aging, provides a potential solution for reducing in vitro expansion and aging of MSCs and improving their therapeutic effects, and also provides a new perspective for anti-MSC aging research.

The invention relates to an antibody specifically bound with S100A8 protein, an antigen binding fragment or a variant thereof, an antibody specifically bound with S100A9 protein, an antigen binding fragment or a variant thereof and application of the antibody and the antigen binding fragment or the variant thereof in preparation of a detection kit for bacterial infectious diseases. The detection kit has high detection sensitivity and specificity on organism bacterial infection, and can be used for detecting bacterial infectious diseases of clinical samples.

The present application provides an anti-S100A8 / A9 antibody and use thereof. The antibody or antigen-binding fragment thereof, and mutants thereof, provided by the present application, can block the biological functions of S100A8 / A9. The antibody or antigen-binding fragment thereof provided by the present application is expected to be developed into a clinical drug, with the aim of reducing the myocardial infarct size in acute myocardial infarction (AMI) patients, lowering the incidence of heart failure, and providing lifelong benefit to the AMI patients. The present application has significant clinical implications and development value.

The application provides application of sophoranol A10 or a pharmaceutically acceptable salt thereof in preparation of an anti-inflammatory product, and a method for inhibiting activation of macrophages in vitro for non-treatment purposes. The application firstly proves that sophoranol A10 has high protein affinity with S100A8 / A9, and can inhibit production of cell inflammatory factors, inhibit activation of macrophages and regulate inflammatory response of the body through a TLR4 / NFκB / MyD88 signal pathway. Therefore, sophoranol A10 can be used for preparation of an anti-inflammatory product, and has a good market application prospect.

Provided are an antibody binding to a dimer of S100A8 and S100A9 or an antigen-binding fragment thereof, and use thereof in treating pancreatitis.

The invention belongs to the technical field of biological medicine, and particularly relates to application of SMOC2 protein in preparation of a medicine for treating psoriasis, the amino acid sequence of the SMOC2 protein is shown as SEQ ID NO.1, it is found that the SMOC2 protein can treat psoriasis, and therefore the application of the SMOC2 protein in preparation of the medicine for treating psoriasis is provided. The SMOC2 protein can be used for treating or improving scales, erythema and thickening phenotypes of skin, inhibiting abnormal proliferation of keratinocytes and expression of inflammatory factors IL1beta, IL23, CAMP, TNF alpha, CXCL2, CXCL3, S100A8 and S100A9, and playing a role in treating or relieving skin inflammatory diseases by inhibiting infiltration of inflammatory cell neutrophils in psoriasis skin lesion tissues.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The invention provides a marker combination for diagnosing sepsis and distinguishing and identifying sepsis and non-infectious systemic inflammation reaction, wherein a marker is selected from one or more of CD177, IL18, MMP8 and S100A8.

The invention relates to a construction method and application of an S100A8 / A9 humanized mouse model. Specifically, the invention relates to an expression vector which comprises a first gene expression cassette for expressing human S100A8 and a second gene expression cassette for expressing human S100A9, and the expression directions of the first gene expression cassette and the second gene expression cassette are opposite. The invention further particularly relates to a method for expressing the S100A8 and S100A9 heterodimers, a construction method of the animal model and application of the animal model constructed according to the method in drug screening or disease mechanism research.